Ionis Reports P-III Study (NEURO-TTRansform) Results of Eplontersen for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
- The company highlighted the 66wk. analysis of the P-III study evaluating eplontersen vs PBO in 168 patients. The study was based on the 35wk. results
- The study met its third co-primary EPs which showed a reduction in serum TTR concentration while TTR reductions, safety, and tolerability profile were consistent with those reported @35wk. The results from 35 & 66wk. analyses will be presented at AAN 2023
- The therapy is being studied in the P-III study (CARDIO-TTRansform) for ATTR-CM. Under the development & commercialization agreement, Ionis & AstraZeneca plan for the regulatory approval of eplontersen for ATTRv-PN in the US and also in the EU and other parts of the world
Ref: Ionis Pharmaceuticals, Inc. | Image: Ionis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].